Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: InvestorLady who wrote (687)	5/3/1998 5:03:00 PM
From: yosi s	Read Replies (2) \| Respond to of 1491

BOL untill recently had only small part of their revenues coming in from their pharmaceutical division. and that was mostly generics. as such they had limited retail detail sales people. Recently BOL refocus, they bought Storz makes equipment for eye surgeons as wellas a division of chiron, this with lotemax and alrex, get them into opthalmologist markets. but at different levels. So this is new to BOL and as such PARS depends on the right policy to be made by BOL. Lets see who comarketing partner will be for Alrex. and how fast they can get Alrex and Lotemax in Europe and LE Tobra (Alrex tobramycin combo, big market.). Also package insert and ads are not out yet. All this was written about previously . The only thing new in Pars is the price drop. This is a great buy. The news on Lotemax was out with preapproval yet the price drop to well below 2$ those that bought did well. This is a repeat. NOT TOO MANY TIMES ONE GETS A SECOND CHANCE TO BUY STOCKS UNDERVALUED.